ArticleWorld journal of urology2026
Comparative safety profiles of enzalutamide, olaparib, and lutetium Lu-177 vipivotide tetraxetan in patients with prostate cancer: a real-world disproportionality analysis of the FAERS database.
Ruitao Li et al.PubMed ↗Publisher ↗
No numbers read from the abstract.